Ignite Creation Date:
2024-05-05 @ 4:45 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00301535
Status:
UNKNOWN
Last Update Posted:
2008-05-16
First Post:
2006-03-09
Brief Title:
A Study of Hemopure to Enhance Tissue Preservation During Cardiopulmonary Bypass Surgery
Sponsor:
Biopure Corporation
Organization:
Biopure Corporation
Study Overview
Official Title:
Enhancement of Tissue Preservation During Cardiopulmonary Bypass With HBOC-201 Registry Study
Status:
UNKNOWN
Status Verified Date:
2008-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if Hemopure will enhance tissue preservation during Cardiopulmonary Bypass surgery
Detailed Description:
The primary objective is to determine the safety and feasibility of administering Hemopure HBOC-201 to reduce myocardial necrosis as measured by CK-MB enzyme elevation and enhance tissue preservation during cardiopulmonary bypass
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None